Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: holds promise + cancer treatment + cancer  Related to the article below (Last Update: 5/5/2008)

Playing The Percentages
Tyler Morning Telegraph, TX - May 3, 2008
Shelley Salvage, a Tylerite who faced the threat of cancer, holds her daughter, Juliana, 1, in the backyard of her home. She eventually opted for a double ...
Lookin' for love: UK pharma gets creative
Business Spectator, Australia -
US-based, London-listed biotech Northwest Biotherapeutics, which is working on a brain cancer vaccine, is currently finalising terms for an $8 million debt ...
Thalidomide set to treat blood cancer in Europe
MarketWatch - Apr 21, 2008
... the introduction of stronger regulation of medications, Celgene says Thalidomide holds further promise for the treatment of blood disorders and cancer. ...
Identification of Novel Tumor Biomarkers Holds Promise for ...
Newswise (press release) - Apr 28, 2008
Newswise ? Brain tumors are the most common solid cancer of childhood and are presently the leading cause of death in children, excluding trauma. ...
Shock Therapy for Depression
Canada Free Press, Canada -
?This research substantiates earlier findings which indicate DBS holds promise and hope for select patients suffering from severe and treatment-resistant ...
Close To Home
WEEK-TV, IL - Apr 24, 2008
Lee has chosen to treat his cancer with radiation, which holds the promise of being as effect as surgery, with fewer side effects. "During the treatment ...
Aethlon Medical and Fusion Capital Execute Private Placement and ...
PR-Inside.com (Pressemitteilung), Austria - May 2, 2008
Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier(R) is able to capture immunosuppressive particles ...OTC:AEMD
Aethlon Medical and Fusion Capital Execute Private Placement and ...
Business Wire (press release), CA - May 2, 2008
... and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, ...OTC:AEMD
A cancer leaves few to lobby
Pittsburgh Post Gazette, PA - Apr 13, 2008
It's not for lack of interest, said Dr. James Doroshow, the institute's director of the division of cancer treatment and diagnosis. ...
BioLineRx Presents BL-1020 Phase 2a Data at Society of Biological ...
Business Wire (press release), CA - May 2, 2008
Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases. ...
Source: Google News

The Proteasome as a Target for Cancer Therapy -
PM Voorhees, EC Dees, BO'Neil, RZ Orlowski - Clinical Cancer Research, 2003 - AACR
... nonmalignant cells. Therefore, proteasome inhibition holds promise as a
novel approach to the treatment of cancer. Inhibitors of ...

… and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with … -
SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, … - Nature Medicine, 1998 - palgrave-journals.com
... antigens has opened new possibilities for the treatment of patients ... peptide vaccines
based on the genes encoding cancer antigens hold promise for the ...

… with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we … -
D Kirn - nature.com
... Correspondence to: D Kirn. Abstract. Replication-selective microbial agents
hold promise as a novel cancer treatment platform. dl1520 ...

… Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment … -
A Jatoi, HE Windschitl, CL Loprinzi, JA Sloan, SR … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org
... holds promise as an appetite stimulant in cancer patients. In addition to this trial,
at least 12 clinical trials have examined dronabinol for the treatment of ...

Integrins: roles in cancer development and as treatment targets -
H Jin, J Varner - British Journal of Cancer, 2004 - nature.com
... Fernando and Hurwitz, 2003), these integrin-based antiangiogenesis therapeutics
hold great promise as powerful therapeutics for the treatment of cancer. ...

Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise? -
T Gruning, C Tiepolt, K Zophel, J Bredow, J Kropp, … - European Journal of Endocrinology, 2003 - eje.org
... Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise? ...
improving (131)I uptake in recurrent/metastasized thyroid cancer with no ...

Surgical options in the treatment of hepatic metastasis from colorectal cancer.
LH Blumgart, Y Fong - Curr Probl Surg, 1995 - ncbi.nlm.nih.gov
... LH, Fong Y. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York ...
Multiple operative modalities hold promise in palliative treatment in the ...

Replication-selective virotherapy for cancer: Biological principles, risk management and future … -
D Kirn, RL Martuza, J Zwiebel - Nature Medicine, 2001 - nature.com
... no longer detectable. Summary Virotherapy holds great promise as a treatment
platform for cancer. Advantages include the potential ...

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC) -
R Pirker, G Krajnik, S Zochbauer, R Malayeri, M … - Annals of Oncology, 1995 - Eur Soc Med Oncology
... advanced or metastatic non- small-cell lung cancer (NSCLC) is not ... drug for the
treatment of NSCLC, holds particularly great promise because both ...

Smart drugs: Tyrosine kinase inhibitors in cancer therapy -
LK Shawver, D Slamon, A Ullrich - Cancer Cell, 2002 - Elsevier
... the success of Gleevec and Herceptin, the impetus for development of new targeted
therapeutics that hold some promise as targets in cancer therapy extends to ...

Source: Google Scholar

Viable Target For Drugs Holds Promise In The Treatment Of Cancers
By bypassing a well-known gene implicated in almost one-third of all cancers and instead focusing on the protein activated by the gene, Duke University Medical Center researchers believe they may have found a new target for anti-cancer drugs.

In experiments with human cells and animal models, the researchers studied the gene known as 'Ras,' which is integral in normal cell growth. When this gene is mutated and becomes overactive, it can lead to the unregulated proliferation of cells that is the hallmark of tumor formation.
The ras gene, known as an oncogene when it is in this mutated state, has been implicated in several different cancers, including those of the pancreas and lungs. To date, efforts at blocking or turning off ras have proven ineffective. Pancreatic cancer has been shown to have the strongest link to the ras oncogene, and it is also one of the hardest cancers to treat, with few patients alive five years after diagnosis, researchers said.

"Since it has been so difficult to target the ras gene itself with drugs, we tried to determine if something that ras activates could be a possible target for a drug or therapy," said Christopher Counter, Ph.D., associate professor of pharmacology and cancer biology and senior member of the research team. "We found a specific target that could be susceptible to drugs, and if these findings are proven true in human trials, we could have a new way of treating ras-dependent cancers."

The results of the Duke experiments were published July 15, 2007, in the journal Genes & Development. Brooke Ancrile, a graduate student in Counter's laboratory, was first author of the paper. The research was supported by the National Institutes of Health.

The researchers discovered that the overactive ras gene was responsible for above-normal secretion of a factor known as interleukin-6 (IL-6). Scientists know a great deal about IL-6 and its functions in the body, but its link to oncogenic ras was unknown.

In addition to finding that the ras oncogene spurred the production of IL-6, they also found that inhibiting IL-6 production reduced the creation of new blood vessels, which are crucial for the development and nourishment of tumors.

"IL-6 was like the gas pedal driving the growth of tumors," Counter said. "No gas, no growth, which is exactly what we saw when we inhibited IL-6 in tumors."

Counter is encouraged that even though these findings are in cell culture and animal models, therapies based on targeting IL-6 in cancers driven by the ras oncogene could be tested in humans in the near future. A biotechnology company has already developed a monoclonal antibody specific to IL-6 which could be used to neutralize IL-6.
A phase II trial is underway testing a monoclonal antibody against IL-6 for patients with multiple myeloma, a cancer that depends on IL-6 but is not known to have a connection to the ras oncogene. If the results of this trial are positive, studies might begin in ras-dependent cancers. Counter's group is actively pursuing the idea that such an antibody may inhibit pancreatic cancer growth in mouse models. If these results are positive, this will open the door for Duke oncologists to organize a clinical trial to test the agent in human cancer patients.

"Secreted proteins promoting the growth of blood vessels in tumors have been successfully neutralized in the past with antibodies," Ancrile said. "We believe that IL-6 is a viable target for drugs that holds promise in the treatment of cancers dependent on the ras oncogene."

Duke's Kian-Huat Lim was also a member of the research team.

Source: Richard Merritt
Duke University Medical Center
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.